Cited by 288Prostate Cancer Treatment and ResearchEstrogen and related hormone effectsSperm and Testicular Function

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.

Open access

Zhu, M.-L., Kyprianou, N.·2008·Endocrine Related Cancer

Open this paper in CoChat — free account Open PDF

Abstract

Androgens promote the growth and differentiation of prostate cells through ligand activation of the androgen receptor (AR). Sensitization of the androgenic response by multifunctional growth factor signaling pathways is one of the mechanisms via which AR contributes to the emergence of androgen-independent prostate tumors. The ability of AR to cross-talk with key growth factor signaling events toward the regulation of cell cycle, apoptosis, and differentiation outcomes in prostate cancer cells is established. In this paper, we review the functional interaction between AR and an array of growth factor signal transduction events (including epidermal growth factor; fibroblast growth factor; IGF1; vascular endothelial growth factor; transforming growth factor-beta) in prostate tumors. The significance of this derailed cross-talk between androgens and key signaling networks in prostate cancer progression and its value as a therapeutic forum targeting androgen-independent metastatic prostate cancer is discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1677/erc-08-0084

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,498
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Hoskins, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U., Liotta, L. A., Falanga, V., & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,867
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Molecular and cellular endocrinology
(1995) · Journal of Endocrinology · doi:10.1677/joe.0.147so19 · Cited by 1,986
Fibroblast growth factors.
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,628
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980

Flagged first, then by citations

Show all 105 references

Sorted by citations

Androgen receptor signaling in prostate cancer development and progression
Tindall, D. J., & Lonergan, P. E. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 544
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 435
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
Menden, M. P., Wang, D. Y. Q., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T. V., Kang, J., Jeon, M., Wolfinger, R. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 371
Inflammation and prostate cancer: the role of interleukin 6 ( IL ‐6)
Nguyen, D. P., Li, J., & Tewari, A. K. (2013) · British Journal of Urology · doi:10.1111/bju.12452 · Cited by 357
Drug resistance in metastatic castration-resistant prostate cancer
Šeruga, B., Ocaña, A., & Tannock, I. F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 346
An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke
Li, S., Overman, J. J., Katsman, D., Kozlov, S. V., Donnelly, C. J., Twiss, J. L., Giger, R. J., Coppola, G., Geschwind, D. H., & Carmichael, S. T. (2010) · Nature Neuroscience · doi:10.1038/nn.2674 · Cited by 329
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 305
Molecular cell biology of androgen receptor signalling
Bennett, N. C., Gardiner, R. A., Hooper, J. D., Johnson, D. W., & Gobe, G. C. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.013 · Cited by 292
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 291
Role of androgens and the androgen receptor in epithelial‐mesenchymal transition and invasion of prostate cancer cells
Zhu, M., & Kyprianou, N. (2009) · The FASEB Journal · doi:10.1096/fj.09-136994 · Cited by 228
Self-citation
Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
Lu, X., Yang, F., Chen, D., Zhao, Q., Chen, D., Ping, H., & Xing, N. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41686 · Cited by 209
LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
Luo, J., Wang, K., Yeh, S., Sun, Y., Liang, L., Xiao, Y., Xu, W., Niu, Y., Liang Cheng, C., Maity, S. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09784-9 · Cited by 205
Angiogenesis in prostate cancer: onset, progression and imaging
Russo, G., Mischi, M., Scheepens, W. A., de la Rosette, J. J. M. C. H., & Wijkstra, H. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11444.x · Cited by 203
The role of progesterone signaling in the pathogenesis of uterine leiomyoma
Kim, J. J., & Sefton, E. C. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.044 · Cited by 191
Epithelial-mesenchymal transition in prostate cancer: an overview
Montanari, M., Rossetti, S., Cavaliere, C., D’Aniello, C., Malzone, M. G., Vanacore, D., Franco, R. D., Mantia, E. L., Iovane, G., Piscitelli, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15686 · Cited by 189
Integration of Regulatory Networks by NKX3-1 Promotes Androgen-Dependent Prostate Cancer Survival
Tan, P. Y., Chang, C. W., Chng, K. R., Wansa, K. D. S. A., Sung, W.-K. K., & Cheung, E. C. W. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05958-11 · Cited by 180
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Yin, L., & Hu, Q. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.274 · Cited by 175
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150
MicroRNAs Profiling in Murine Models of Acute and Chronic Asthma: A Relationship with mRNAs Targets
Garbacki, N., Valentin, E. D., Huynh‐Thu, V. A., Geurts, P., Irrthum, A., Crahay, C., Arnould, T., Deroanne, C., Piette, J. G., Cataldo, D. D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016509 · Cited by 151
Growth Hormone’s Links to Cancer
Boguszewski, C. L., & Boguszewski, M. C. D. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00166 · Cited by 147
Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer
Mishra, S., Deng, J., Gowda, P. S., Rao, M. K., Lin, C.-L., Chen, C., Huang, T. H. ‐., & Sun, L. (2013) · Oncogene · doi:10.1038/onc.2013.374 · Cited by 145
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
Wang, R., Sun, Y., Li, L., Niu, Y., Lin, W.-Y., Lin, C.-Y., Antonarakis, E. S., Luo, J., Yeh, S., & Chang, C. (2017) · European Urology · doi:10.1016/j.eururo.2017.04.005 · Cited by 141
Recent insights into NF ‐κ B signalling pathways and the link between inflammation and prostate cancer
Nguyen, D. P., Li, J., Yadav, S. S., & Tewari, A. K. (2013) · British Journal of Urology · doi:10.1111/bju.12488 · Cited by 141
Altered Signaling Pathways in Prostate Cancer Drive Metabolic Fate
Antico Arciuch, V. G., Gueron, G., Cotignola, J. H., & Vazquez, E. S. (2017) · CONICET Digital (CONICET) · Cited by 139
Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
Traish, A. M., & Morgentaler, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605376 · Cited by 137
The Influence of Sex Hormones in Liver Function and Disease
Kasarinaite, A., Sinton, M. C., Saunders, P. T. K., & Hay, D. C. (2023) · Cells · doi:10.3390/cells12121604 · Cited by 139
Posttranslational Modification of the Androgen Receptor in Prostate Cancer
der Steen, T. V., Tindall, D. J., & Huang, H. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714833 · Cited by 140
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles
Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W. A., & Nevalainen, M. T. (2016) · Oncotarget · doi:10.18632/oncotarget.12554 · Cited by 132
Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
Rothermundt, C. A., Hayoz, S., Templeton, A. J., Winterhalder, R., Strebel, R. T., Bärtschi, D., Pollak, M., Lui, L., Endt, K., Schiess, R., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.057 · Cited by 123
Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
Marques, R. B., Dits, N. F. J., Erkens‐Schulze, S., van Weerden, W. M., & Jenster, G. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013500 · Cited by 124
Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression
Jones, E., Pu, H., & Kyprianou, N. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802705696 · Cited by 109
Self-citation
Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
Abidi, A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119704 · Cited by 107
Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation
Sen, A., Castro, I. D., DeFranco, D. B., Deng, F.-M., Melamed, J., Kapur, P., Raj, G. V., Rossi, R. M., & Hammes, S. R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62044 · Cited by 103
Receptor-Targeted Nanomedicine for Cancer Therapy
Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D. M., & Kommineni, N. (2024) · Receptors · doi:10.3390/receptors3030016 · Cited by 101
Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Wang, X., Lee, S. O., Xia, S., Jiang, Q., Luo, J., Li, L., Yeh, S., & Chang, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0895 · Cited by 95
Paxillin Regulates Androgen- and Epidermal Growth Factor-induced MAPK Signaling and Cell Proliferation in Prostate Cancer Cells
Sen, A., O’Malley, K. J., Wang, Z., Raj, G. V., DeFranco, D. B., & Hammes, S. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134064 · Cited by 89
Mechanisms navigating the TGF-β pathway in prostate cancer
Cao, Z., & Kyprianou, N. (2015) · Asian journal of urology · doi:10.1016/j.ajur.2015.04.011 · Cited by 91
Self-citation
Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer
Chakravarty, G., Moroz, K., Makridakis, N. M., Lloyd, S. A., Galvez, S. E., Canavello, P. R., Lacey, M. R., Agrawal, K. C., & Mondal, D. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010086 · Cited by 86
Androgen receptor signaling regulates growth of glioblastoma multiforme in men
Yu, X., Jiang, Y., Wei, W., Cong, P., Ding, Y., Xiang, L., & Wu, K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2709-z · Cited by 86
CYP17A1 inhibitors in castration-resistant prostate cancer
Gomez, L., Kovac, J. R., & Lamb, D. J. (2015) · Steroids · doi:10.1016/j.steroids.2014.12.021 · Cited by 84
The FGF/FGFR system in the physiopathology of the prostate gland
Giacomini, A., Grillo, E., Rezzola, S., Ribatti, D., Rusnati, M., Ronca, R., & Presta, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00005.2020 · Cited by 81
Transcriptional network of androgen receptor in prostate cancer progression
Takayama, K., & Inoue, S. (2013) · International Journal of Urology · doi:10.1111/iju.12146 · Cited by 83
From pathogenesis to prevention of castration resistant prostate cancer
Bonkhoff, H., & Berges, R. R. (2009) · The Prostate · doi:10.1002/pros.21042 · Cited by 78
Testosterone Promotes Glioblastoma Cell Proliferation, Migration, and Invasion Through Androgen Receptor Activation
Rodríguez-Lozano, D. C., Piña-Medina, A. G., Hansberg-Pastor, V., Bello‐Alvarez, C., & Camacho‐Arroyo, I. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00016 · Cited by 78
Targeting silibinin in the antiproliferative pathway
Li, L., Zeng, J., Gao, Y., & He, D. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903533631 · Cited by 76
Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf
Pitchakarn, P., Suzuki, S., Ogawa, K., Pompimon, W., Takahashi, S., Asamoto, M., Limtrakul, P., & Shirai, T. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.041 · Cited by 76
Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome
Sullivan, D. A., Dana, R., Sullivan, R. M., Krenzer, K. L., Şahin, A., Arica, B., Liu, Y., Kam, W. R., Papas, A., & Cermak, J. M. (2018) · Ophthalmic Research · doi:10.1159/000487487 · Cited by 76
Persistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 77
aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6
Ishiguro, H., Akimoto, K., Nagashima, Y., Kojima, Y., Sasaki, T., Ishiguro-Imagawa, Y., Nakaigawa, N., Ohno, S., Kubota, Y., & Uemura, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907044106 · Cited by 74
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 78
The activation of OR51E1 causes growth suppression of human prostate cancer cells
Maßberg, D., Jovancevic, N., Offermann, A., Simon, A., Baniahmad, A., Perner, S., Pungsrinont, T., Luko, K., Philippou, S., Ubrig, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10197 · Cited by 73
Androgen receptor‐related diseases: what do we know?
Shukla, G. C., Plaga, A. R., Shankar, E., & Gupta, S. (2016) · Andrology · doi:10.1111/andr.12167 · Cited by 77
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.23 · Cited by 74
The role of proteomics in prostate cancer research: Biomarker discovery and validation
Pin, E., Fredolini, C., & Petricoin, E. F. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.12.012 · Cited by 71
Overcoming Chemotherapy Resistance in Prostate Cancer
Madan, R. A., Pal, S. K., Sartor, O. A., & Dahut, W. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2654 · Cited by 71
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Ferrari, A. C., Alumkal, J. J., Stein, M. N., Taplin, M., Babb, J. S., Barnett, E. S., Gómez-Pinillos, A., Liu, X., Moore, D. F., DiPaola, R. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1589 · Cited by 71
In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor
Singh, P., & Bast, F. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1090-1 · Cited by 69
Suppressed Prostate Epithelial Development with Impaired Branching Morphogenesis in Mice Lacking Stromal Fibromuscular Androgen Receptor
Lai, K.-P., Yamashita, S., Vitkus, S., Shyr, C., Yeh, S., & Chang, C. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1189 · Cited by 67
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review
Özkan, E. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.002 · Cited by 67
Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
Damodaran, S., Kyriakopoulos, C. E., & Jarrard, D. F. (2017) · Urologic Clinics of North America · doi:10.1016/j.ucl.2017.07.008 · Cited by 68
Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
Ruiz de Porras, V., Font, A., & Aytes, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.033 · Cited by 65
Androgen Therapy in Neurodegenerative Diseases
Bianchi, V. E., Rizzi, L., Bresciani, E., Omeljaniuk, R. J., & Torsello, A. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa120 · Cited by 69
Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer
Ray, K., Újvári, B., Ramana, V., & Donald, J. A. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.002 · Cited by 64
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands
Carrión-Salip, D., Panosa, C., Menéndez, J. A., Puig, T., Oliveras, G., Pandiella, A., Llorens, R., & Massaguer, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1509 · Cited by 62
The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer
Melnik, B. C., John, S. M., Carrera‐Bastos, P., & Cordain, L. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-74 · Cited by 63
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1548 · Cited by 61
FOXA1 Promotes Tumor Progression in Prostate Cancer via the Insulin-Like Growth Factor Binding Protein 3 Pathway
Imamura, Y., Sakamoto, S., Endo, T., Utsumi, T., Fuse, M., Suyama, T., Kawamura, K., Imamoto, T., Yano, K., Uzawa, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042456 · Cited by 60
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Chen, M., Feuerstein, M. A., Levina, E. M., Baghel, P. S., Carkner, R. D., Tanner, M. J., Shtutman, M. S., Vacherot, F., Terry, S., TAILLE, A. D. L., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-89 · Cited by 59
Glycosylation is a global target for androgen control in prostate cancer cells
Munkley, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0569 · Cited by 60
Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
Lohiya, V., Aragon‐Ching, J. B., & Sonpavde, G. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34535 · Cited by 60
Anti-androgen hormonal therapy for cancer and other diseases
Student, S., Hejmo, T., Poterała-Hejmo, A., Leśniak, A., & Bułdak, R. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172783 · Cited by 63
Role of Proprotein Convertases in Prostate Cancer Progression
Couture, F., D’Anjou, F., Desjardins, R., Boudreau, F., & Day, R. W. (2012) · Neoplasia · doi:10.1593/neo.121368 · Cited by 58
Mesenchymal stem cells and the embryonic reawakening theory of BPH
Brennen, W. N., & Isaacs, J. T. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0087-9 · Cited by 58
Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)
Quiles, M., Arbos, M. A., Fraga, A., de Torres, I. M., Reventós, J., & Moróte, J. (2010) · The Prostate · doi:10.1002/pros.21138 · Cited by 57
Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents
Joshi, G., Singh, P. K., Negi, A., Rana, A., Singh, S., & Kumar, R. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.08.009 · Cited by 56
Role of miRNALet-7and Its Major Targets in Prostate Cancer
Wagner, S., Ngezahayo, A., Escobar, H. M., & Nolte, I. J. A. (2014) · BioMed Research International · doi:10.1155/2014/376326 · Cited by 60
Pharmacologic Inhibition of Jak2–Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer
Gu, L., Liao, Z., Hoang, D. T., Dagvadorj, A., Gupta, S., Blackmon, S. M., Ellsworth, E., Talati, P. G., Leiby, B. E., Zinda, M. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0422 · Cited by 55
Cedrol suppresses glioblastoma progression by triggering DNA damage and blocking nuclear translocation of the androgen receptor
Chang, K., Huang, X., Chang, J. T., Huang, Y., Weng, J., & Tsai, N. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.007 · Cited by 55
Epigenetic repression of regulator of G‐protein signaling 2 promotes androgen‐independent prostate cancer cell growth
Wolff, D. W., Xie, Y., Deng, C., Gatalica, Z., Yang, M., Wang, B., Wang, J., Lin, M., Abel, P. W., & Tu, Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.26138 · Cited by 52
Factors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate Cancer
Bonkhoff, H. (2011) · Prostate Cancer · doi:10.1155/2012/593241 · Cited by 49
Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets
Ramalingam, S., Ramamurthy, V. P., & Njar, V. C. O. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.07.006 · Cited by 51
Unveiling the Association of STAT3 and HO-1 in Prostate Cancer: Role beyond Heme Degradation
Elguero, B., Gueron, G., Giudice, J., Toscani, A. M., Luca, P. D., Zalazar, F., Leskow, F. C., Meiss, R. P., Navone, N. M., Siervi, A. D., et al. (2012) · Neoplasia · doi:10.1593/neo.121358 · Cited by 48
Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance
Li, C., Cheng, D., & Li, P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1542811 · Cited by 48
Androgens Accentuate TGF‐β Dependent Erk/Smad Activation During Thoracic Aortic Aneurysm Formation in Marfan Syndrome Male Mice
Tashima, Y., He, H., Cui, J. Z., Pedroza, A. J., Nakamura, K., Yokoyama, N., Iosef, C., Burdon, G., Koyano, T. K., Yamaguchi, A., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015773 · Cited by 44
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
Maitland, N. J. (2021) · Cancers · doi:10.3390/cancers13020327 · Cited by 44
Paper/PMMA Hybrid 3D Cell Culture Microfluidic Platform for the Study of Cellular Crosstalk
Lei, K. F., Chang, C.-H., & Chen, M. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03021 · Cited by 44
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)
Barata, P. C., Cooney, M. M., Tyler, A. J., Wright, J., Dreicer, R., & Garcia, J. A. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0574-0 · Cited by 42
The In Vitro and In Vivo Anti-Cancer Activities of a Standardized Quassinoids Composition from Eurycoma longifolia on LNCaP Human Prostate Cancer Cells
Tong, K.-L., Chan, K., AbuBakar, S., Low, B., Ma, H. Q., & Wong, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121752 · Cited by 42
Redox-Mediated and Ionizing-Radiation-Induced Inflammatory Mediators in Prostate Cancer Development and Treatment
Miao, L., Holley, A. K., Zhao, Y., Clair, W. H. S., & Clair, D. K. S. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5637 · Cited by 42
miR-618 Inhibits Prostate Cancer Migration and Invasion by Targeting FOXP2
Song, X., Tang, Y., Lei, X.-H., Zhao, S., & Wu, Z. (2017) · Journal of Cancer · doi:10.7150/jca.17407 · Cited by 41
Antisense oligonucleotide targeting of insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancer
Furukawa, J., Wraight, C. J., Freier, S. M., Peralta, E. M., Atley, L. M., Monia, B. P., Gleave, M. E., & Cox, M. (2009) · The Prostate · doi:10.1002/pros.21054 · Cited by 40
The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer
Brizzolara, A., Benelli, R., Venè, R., Barboro, P., Poggi, A. D., Tosetti, F., & Ferrari, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.025 · Cited by 39
Prostate cancer: the need for biomarkers and new therapeutic targets
Felgueiras, J., Silva, J. V., & Fardilha, M. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1300106 · Cited by 38
Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo
Sasaki, T., Nakashiro, K., Tanaka, H., Azuma, K., Goda, H., Hara, S., Onodera, J., Fujimoto, I., Tanji, N., Yokoyama, M., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.045 · Cited by 36
SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma
Villalobos-Hernandez, A., Bobbala, D., Kandhi, R., Khan, M. G. M., Mayhue, M., Dubois, C. M., Ferbeyre, G., Saucier, C., Ramanathan, S., & Ilangumaran, S. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.50 · Cited by 35
Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies
Singla, R. K., Sharma, P., Dubey, A. K., Gundamaraju, R., Kumar, D., Kumar, S., Madaan, R., Shri, R., Tsagkaris, C., Parisi, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732266 · Cited by 35
Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
Das, K., Lorena, P. D. N., Ng, L. K., Lim, D. G. S., Shen, L., Siow, W. Y., Teh, M., Reichardt, J. K. V., & Salto‐Tellez, M. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0022 · Cited by 35
Gartanin, an isoprenylated xanthone from the mangosteen fruit (Garcinia mangostana), is an androgen receptor degradation enhancer
Li, G., Petiwala, S. M., Yan, M., Won, J. H., Petukhov, P. A., & Johnson, J. J. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600037 · Cited by 34
Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells
Recouvreux, M. V., Wu, B. J., Gao, A. C., Zonis, S., Chesnokova, V., Bhowmick, N. A., Chung, L. W. K., & Melmed, S. K. (2017) · Endocrinology · doi:10.1210/en.2016-1939 · Cited by 35
The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
Sasaki, T., & Sugimura, Y. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120565 · Cited by 35

Authors: Zhu, M.-L., & Kyprianou, N.
Affiliations: University of Kentucky HealthCare (US)
ORCID: Zhu, M.-L.
Kyprianou, N.
Venue: Endocrine Related Cancer
Publisher: Bioscientifica
Published: 2008-09-10
Volume: 15
Issue: 4
Pages: 841-849
ISSN: 1351-0088 (ISSN-L)
1479-6821
DOI: 10.1677/erc-08-0084
PMC: PMC2740735
OpenAlex: W2167609397
Cited by: 286
References: 105
Citations by year: 2026: 3 · 2025: 10 · 2024: 12 · 2023: 16 · 2022: 12 · 2021: 16 · 2020: 9 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 23 · 2014: 10 · 2013: 29 · 2012: 17
FWCI: 3.48
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Endocrine Related Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK-53525-08, R01DK053525)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
Keywords: androgen receptor, growth factor signaling, signaling crosstalk, prostate cancer, castration-resistant prostate cancer, metastatic prostate cancer, epidermal growth factor, fibroblast growth factor, insulin-like growth factor I, vascular endothelial growth factor, TGF-beta, cell cycle regulation, apoptosis, therapeutic target
MeSH terms: Animals, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Gene Expression Regulation, Neoplastic, Receptor Cross-Talk, Intercellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks